Simultaneous detection of cannibalism and senescence as prognostic marker for cancer
US-2015185202-A1 · Jul 2, 2015 · US
Use of minaprine to reduce tumor growth
US11517575B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11517575-B2 |
| Application number | US-201916963338-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 23, 2019 |
| Priority date | Jan 23, 2017 |
| Publication date | Dec 6, 2022 |
| Grant date | Dec 6, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is drawn to the use of Minaprine dihydrochloride and analogs thereof, for reducing tumor growth when administered to a patient suffering from cancer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating cancer in a subject in need thereof, said method comprising the step of administering to said subject an effective amount of minaprine dihydrochloride. 2. The method according to claim 1 , wherein said cancer is brain cancer, gastric cancer, head-and-neck cancer, pancreatic cancer, non-small cell lung cancer, small cell lung cancer, prostate cancer, colon cancer, non-Hodgkin's lymphoma, sarcoma, testicular cancer, acute non-lymphocytic leukemia or breast cancer. 3. The method according to claim 1 , wherein said minaprine dihydrochloride is in the form of an injectable pharmaceutical composition. 4. The method according to claim 3 , wherein said administering step comprises systemic administration. 5. The method according to claim 3 , wherein said administering step comprises intra-tumoral administration. 6. The method according to claim 1 , wherein the cancer is gastric cancer, pancreatic cancer, prostate cancer, colon cancer, testicular cancer, and breast cancer. 7. The method according to claim 3 , wherein the cancer is brain cancer, head-and-neck cancer, non-small cell lung cancer, small cell lung cancer, non-Hodgkin's lymphoma, sarcoma, and acute non-lymphocytic leukemia.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Detection of programmed cell death, i.e. apoptosis · CPC title
specific for leukemia · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
- G01N33/5011Primary
for testing antineoplastic activity · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11517575B2 cover?
- The present invention is drawn to the use of Minaprine dihydrochloride and analogs thereof, for reducing tumor growth when administered to a patient suffering from cancer.
- Who is the assignee on this patent?
- Roussy Inst Gustave
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5011. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).